We are live on ! Find out more
HAE icon

Haemonetics

298 hedge funds and large institutions have $4.37B invested in Haemonetics in 2024 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 104 increasing their positions, 115 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more call options, than puts

Call options by funds: $14.6M | Put options by funds: $5.04M

1% more funds holding

Funds holding: 295298 (+3)

8% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 40

0.26% more ownership

Funds ownership: 100.53%100.79% (+0.26%)

0% more capital invested

Capital invested by funds: $4.36B → $4.37B (+$6.27M)

10% less repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 115

Holders
298
Holders Change
+3
Holders Change %
+1.02%
% of All Funds
4.29%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
43
Increased
104
Reduced
115
Closed
40
Calls
$14.6M
Puts
$5.04M
Net Calls
+$9.59M
Net Calls Change
-$1.66M
Name Holding Trade Value Shares
Change
Change in
Stake
AQR Capital Management
51
AQR Capital Management
Connecticut
$10.9M -$796K -10,143 -7%
SEI Investments
52
SEI Investments
Pennsylvania
$10.5M -$309K -3,939 -3%
IECM
53
Intrinsic Edge Capital Management
Illinois
$10.2M +$9.42M +120,000 New
Nordea Investment Management
54
Nordea Investment Management
Sweden
$10.2M -$205K -2,618 -2%
AllianceBernstein
55
AllianceBernstein
Tennessee
$9.36M -$101K -1,281 -1%
Barclays
56
Barclays
United Kingdom
$8.86M -$1.18M -15,034 -13%
Swiss National Bank
57
Swiss National Bank
Switzerland
$8.53M
Invesco
58
Invesco
Georgia
$8.46M -$48.4M -616,804 -86%
AIG
59
American International Group
New York
$7.81M -$120K -1,528 -2%
PHP
60
Parkman Healthcare Partners
Connecticut
$7.76M +$1.65M +21,022 +30%
Balyasny Asset Management
61
Balyasny Asset Management
Illinois
$7.74M +$3.51M +44,728 +97%
EGM
62
Engineers Gate Manager
New York
$7.63M +$6.36M +81,019 +967%
CS
63
Credit Suisse
Switzerland
$7.53M +$100K +1,275 +1%
Marshall Wace
64
Marshall Wace
United Kingdom
$6.95M +$2.12M +27,018 +50%
Legal & General Group
65
Legal & General Group
United Kingdom
$6.92M +$90.1K +1,148 +1%
ACM
66
American Capital Management
New York
$6.85M -$54.9K -700 -0.9%
Point72 Asset Management
67
Point72 Asset Management
Connecticut
$6.72M -$579K -7,383 -9%
Citigroup
68
Citigroup
New York
$6.61M -$5.71M -72,759 -48%
Comerica Bank
69
Comerica Bank
Texas
$6.3M -$756K -9,629 -12%
Man Group
70
Man Group
United Kingdom
$6.2M +$2.75M +35,034 +93%
Manulife (Manufacturers Life Insurance)
71
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$6.15M +$989K +12,601 +21%
New York State Teachers Retirement System (NYSTRS)
72
New York State Teachers Retirement System (NYSTRS)
New York
$5.97M -$202K -2,572 -4%
UBS AM
73
UBS AM
Illinois
$5.85M +$619K +7,885 +13%
Allianz Asset Management
74
Allianz Asset Management
Germany
$5.65M +$393K +5,007 +8%
Two Sigma Advisers
75
Two Sigma Advisers
New York
$5.34M -$5.32M -67,800 -52%

HAE Hedge Fund Activity: Q1 2024 in Review

298 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2024, worth a combined $4.37B — up 0.14% from $4.36B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new HAE positions and 40 closed out — a net gain of 3 holders — while 104 added to existing stakes and 115 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $78.7M. The largest seller was Fidelity Investments, cutting an estimated $109M.

  • 298 institutional investors held Haemonetics (HAE) as of Q1 2024, up from 295 in Q4 2023.
  • Funds reported $4.37B of Haemonetics stock for Q1 2024, up 0.14% quarter-over-quarter.
  • 43 funds opened new Haemonetics positions in Q1 2024 and 40 closed out, a net change of +3 holders.
  • The largest Haemonetics buyer in Q1 2024 was Wellington Management Group, an estimated $78.7M added.
  • The largest Haemonetics seller in Q1 2024 was Fidelity Investments, an estimated $109M sold.

Based on aggregated 13F filings for Q1 2024.